[go: up one dir, main page]

AR119715A1 - Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona - Google Patents

Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Info

Publication number
AR119715A1
AR119715A1 ARP200101015A ARP200101015A AR119715A1 AR 119715 A1 AR119715 A1 AR 119715A1 AR P200101015 A ARP200101015 A AR P200101015A AR P200101015 A ARP200101015 A AR P200101015A AR 119715 A1 AR119715 A1 AR 119715A1
Authority
AR
Argentina
Prior art keywords
dioxopiperidin
isoindolin
hodgkin
dione
lymphoma
Prior art date
Application number
ARP200101015A
Other languages
English (en)
Inventor
Michael Pourdehnad
Rama Krishna Narla
Antonia Lopez-Girona
Tonia J Buchholz
Anton Maria Soraya Carrancio
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR119715A1 publication Critical patent/AR119715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos para usar 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona, o un enantiómero, una mezcla de enantiómeros, un tautómero, un isotopólogo o una sal de aquella aceptable desde el punto de vista farmacéutico, solos o en combinación con rituximab, para tratar, prevenir o controlar el linfoma no Hodgkin.
ARP200101015A 2019-04-12 2020-04-08 Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona AR119715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
AR119715A1 true AR119715A1 (es) 2022-01-05

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101015A AR119715A1 (es) 2019-04-12 2020-04-08 Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Country Status (19)

Country Link
US (3) US11390617B2 (es)
EP (1) EP3952880B1 (es)
JP (1) JP7562557B2 (es)
KR (1) KR20210151895A (es)
CN (1) CN114144182B (es)
AR (1) AR119715A1 (es)
AU (1) AU2020270917B2 (es)
BR (1) BR112021020372A2 (es)
CA (1) CA3132538A1 (es)
CL (1) CL2021002651A1 (es)
FI (1) FI3952880T3 (es)
IL (1) IL287145A (es)
LT (1) LT3952880T (es)
MA (1) MA55608A (es)
MX (1) MX2021012507A (es)
SG (1) SG11202111232RA (es)
TW (1) TWI853014B (es)
WO (1) WO2020210418A1 (es)
ZA (1) ZA202107668B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282886B2 (en) 2018-11-08 2025-07-01 Juno Therapeutics Inc Methods and combinations for T-cell therapy and modulation
CN115087448A (zh) 2019-10-21 2022-09-20 新基公司 使用2-(2,6-二氧代哌啶-3-基-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗血液恶性肿瘤的方法
US11628172B2 (en) * 2019-10-21 2023-04-18 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
JP7662625B2 (ja) * 2019-10-21 2025-04-15 セルジーン コーポレーション 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
EP4048666A1 (en) * 2019-10-21 2022-08-31 Celgene Corporation Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
CA3154908A1 (en) * 2019-10-21 2021-04-29 Sreenivas S. Bhat Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam
MX2022004729A (es) * 2019-10-21 2022-05-13 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y segundos principios activos para uso combinado.
JP2024513054A (ja) * 2021-03-29 2024-03-21 ジュノー セラピューティクス インコーポレイテッド リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ
AU2022260522A1 (en) * 2021-04-21 2023-09-21 Bristol-Myers Squibb Company Methods of treating b-cell lymphoma using combination therapy
TW202308644A (zh) * 2021-04-21 2023-03-01 美商西建公司 使用2-(2,6-二氧六氫吡啶-3-基)-4-((2-氟-4-((3-嗎啉基氮雜環丁烷-1-基)甲基)苄基)胺基)異吲哚啉-1,3-二酮治療非霍奇金氏淋巴瘤的方法
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
DK2076260T3 (da) * 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
HUE043862T2 (hu) 2009-05-19 2021-12-28 Celgene Corp 4-Amino-2-(2,6-dioxopiperidin-3-il)-izoindolin-l,3-diont tartalmazó készítmények
SG10202012179RA (en) * 2010-02-11 2021-01-28 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
SG10202108516PA (en) 2012-08-09 2021-09-29 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
JP2015535291A (ja) 2012-11-05 2015-12-10 セルジーン コーポレイション 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療
JP6469077B2 (ja) * 2013-04-02 2019-02-13 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
DK3643709T3 (da) 2014-10-30 2021-12-20 Kangpu Biopharmaceuticals Inc Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
TWI830576B (zh) * 2017-07-10 2024-01-21 美商西建公司 抗增生化合物及其使用方法
SI3784663T1 (sl) * 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma

Also Published As

Publication number Publication date
US12103923B2 (en) 2024-10-01
TW202103705A (zh) 2021-02-01
WO2020210418A1 (en) 2020-10-15
US20220324855A1 (en) 2022-10-13
SG11202111232RA (en) 2021-11-29
AU2020270917A1 (en) 2021-11-04
TWI853014B (zh) 2024-08-21
JP7562557B2 (ja) 2024-10-07
EP3952880B1 (en) 2025-12-10
AU2020270917B2 (en) 2025-08-28
US20240400548A1 (en) 2024-12-05
FI3952880T3 (fi) 2026-02-05
CN114144182A (zh) 2022-03-04
CA3132538A1 (en) 2020-10-15
US11390617B2 (en) 2022-07-19
US20200325129A1 (en) 2020-10-15
EP3952880A1 (en) 2022-02-16
LT3952880T (lt) 2026-01-26
JP2022527398A (ja) 2022-06-01
IL287145A (en) 2021-12-01
CN114144182B (zh) 2024-05-24
MX2021012507A (es) 2022-01-24
KR20210151895A (ko) 2021-12-14
MA55608A (fr) 2022-02-16
ZA202107668B (en) 2025-01-29
CL2021002651A1 (es) 2022-04-29
BR112021020372A2 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
AR119715A1 (es) Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
ZA201903125B (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MX2019003098A (es) Composicion farmaceutica.
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
UY33397A (es) Forma sólida de un naftaleno carboxamida
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT200600359A (es) Fungicidal n-[2-(haloalkoxy)phenyl]heteroarylcarboxamides
ZA202204446B (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
MX2022004683A (es) Metodos de tratamiento de neoplasias hematologicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
MX2023012294A (es) Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona.
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
ZA201904033B (en) Pharmaceutical compounds
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent